


Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma

Adriana Olar¹  · Khalida M. Wani² · Charmaine D. Wilson³ · Gelareh Zadeh⁴ · Franco DeMonte⁵ · David T. W. Jones⁶ · Stefan M. Pfister^{6,7} · Erik P. Sulman^{2,8} · Kenneth D. Aldape⁴

Received: 19 November 2016 / Revised: 16 January 2017 / Accepted: 17 January 2017
© Springer-Verlag Berlin Heidelberg 2017

Abstract Meningioma is the most common primary brain tumor and carries a substantial risk of local recurrence. Methylation profiles of meningioma and their clinical implications are not well understood. We hypothesized that aggressive meningiomas have unique DNA methylation patterns that could be used to better stratify patient management. Samples ($n = 140$) were profiled using the Illumina HumanMethylation450BeadChip. Unsupervised modeling on a training set ($n = 89$) identified 2 molecular methylation subgroups of meningioma (MM) with significantly different recurrence-free survival (RFS) times between the groups: a prognostically unfavorable subgroup (MM-UNFAV) and a prognostically favorable

subgroup (MM-FAV). This finding was validated in the remaining 51 samples and led to a baseline meningioma methylation classifier (bMMC) defined by 283 CpG loci (283-bMMC). To further optimize a recurrence predictor, probes subsumed within the baseline classifier were subject to additional modeling using a similar training/validation approach, leading to a 64-CpG loci meningioma methylation predictor (64-MMP). After adjustment for relevant clinical variables [WHO grade, mitotic index, Simpson grade, sex, location, and copy number aberrations (CNAs)] multivariable analyses for RFS showed that the baseline methylation classifier was not significant ($p = 0.0793$). The methylation predictor, however, was significantly associated with tumor recurrence ($p < 0.0001$). CNAs were extracted from the 450k intensity profiles. Tumor samples in the MM-UNFAV subgroup showed an overall higher proportion of CNAs compared to the MM-FAV subgroup tumors and the CNAs were complex in nature. CNAs in the MM-UNFAV subgroup included recurrent losses of 1p, 6q, 14q and 18q, and gain of 1q, all of which were previously

This work has been presented at the Society of Neuro-Oncology Conference on Meningioma, Toronto, ON, Canada, June, 2016.

E. P. Sulman and K. D. Aldape contributed equally.

Electronic supplementary material The online version of this article (doi:[10.1007/s00401-017-1678-x](https://doi.org/10.1007/s00401-017-1678-x)) contains supplementary material, which is available to authorized users.

✉ Adriana Olar
adriana_olar@yahoo.com; olar@musc.edu

¹ Departments of Pathology and Laboratory Medicine and Neurosurgery, Medical University of South Carolina and Hollings Cancer Center, 171 Ashley Ave., MSC 908, Charleston, SC 29425, USA

² Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 W Holcombe Blvd., Houston, TX 77030, USA

³ Center for Nursing Research, The University of Texas School of Nursing, 6901 Bertner St., Houston, TX 77030, USA

⁴ Princess Margaret Cancer Centre, MacFeeters-Hamilton Brain Tumour Centre, College Street 101, Toronto M5G 1L7, ON, Canada

⁵ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

⁶ Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Network (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

⁷ Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany

⁸ Departments of Radiation Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

identified as indicators of poor outcome. In conclusion, our analyses demonstrate robust DNA methylation signatures in meningioma that correlate with CNAs and stratify patients by recurrence risk.

Keywords Meningioma · Epigenetics · DNA methylation · Recurrence risk · Copy number aberrations · Molecular subgroups

Introduction

Meningiomas are thought to arise from the arachnoid (meningothelial) cells in the leptomeninges. They are the most common primary tumors of the central nervous system (CNS) and can cause significant morbidity and poor quality of life for selected patients [59]. Meningiomas have diverse morphological spectra with both epithelial and mesenchymal features. Currently meningioma is classified based on histomorphological criteria of proliferation (i.e., mitotic rate), brain invasion, and morphological aspects into 3 World Health Organization (WHO) grades [41]. The strongest predictors of tumor recurrence to date are the WHO grade and the extent of surgical resection (Simpson grade) [24, 52, 66]; however, there is significant within-grade variation of recurrence risk for individual patients. While in general the recurrence rate increases with the WHO grade, there are subsets of patients with WHO I meningioma who experience early tumor recurrence and rare patients with WHO grade III who do not experience recurrence at all. However, the most challenging group of patients from a clinical management perspective are those with WHO grade II tumors where recurrence is expected in approximately 40% of cases. It is hard to accurately predict tumor recurrence for individual patients with atypical meningioma and therefore is difficult to decide which patients should receive adjuvant radiation therapy versus close monitoring by imaging [2, 17, 41, 43, 54, 72].

Although numerous molecular alterations have been described in meningioma [1, 9, 10, 13, 16, 62, 65] few of which were linked to prognosis, like 1p36 loss [39, 45], 9p21 loss [61], complex karyotypes [17, 45], and recently *TERT* promoter mutations [65], these alterations are not yet integrated with the morphological diagnosis in the most recent, revised WHO classification [41] and molecular testing is not routinely performed in the clinic for patients with meningioma. Meningioma recurrence may warrant adjuvant radiation therapy or increased monitoring [54], but these patients are not accurately identified by the current meningioma classification system. In a similar way those not at risk for meningioma recurrence could be spared the toxicity of radiation therapy if accurately identified. The neuro-oncology community is in need of a better, more

robust, perhaps molecular stratification system that could better tailor risk of recurrence and modulate therapy for patients with meningioma.

Methylation profiling of solid tumors has revealed biological subtypes, often with clinical implications [5, 25–29, 31, 36, 37, 42, 48, 51, 57, 64, 67, 68, 70, 71, 73]. However, little is known about global methylation profiles of meningioma [21, 35, 74], and their clinical implications are not yet well understood. Moreover, a deeper understanding of methylation in meningioma may increase our understanding regarding meningioma tumorigenesis.

In an attempt to address these issues and improve upon the current methods of risk stratification in meningioma, we hypothesized that aggressive meningiomas have unique DNA methylation profiles, with the potential for clinical relevance that could be used to better stratify patients. To test this hypothesis we have profiled a group of 140 meningioma samples of all histologic grades using the Illumina HumanMethylation450 BeadChip, and have compared these findings with clinical outcome. We identified robust DNA methylation patterns that stratify patients by recurrence risk.

Materials and methods

Data collection and tissue samples

This study was approved and carried out in accordance with institutional review board guidelines. One hundred and forty formalin-fixed paraffin embedded (FFPE) meningioma tissue samples were retrospectively collected. The samples were elected based on tissue availability and availability of detailed clinical information. The following samples were not included: radiation-induced meningiomas, meningiomas of special morphological subtypes (with grade implication—clear cell, chordoid, rhabdoid, papillary; without grade implication—microcystic, secretory, angiomatous, psammomatous, lymphoplasmacyte-rich, metaplastic), meningioangiomatosis, spinal cord meningiomas, syndromic meningiomas (patients with a clinical diagnosis of neurofibromatosis type 2). Hematoxylin and eosin (H&E) slides were reviewed and the meningioma diagnosis was confirmed by two experienced neuropathologists (AO and KDA). Tumors collected pre-2007 were re-graded according to the 2007 WHO criteria [40]. Tumors with brain invasion in absence of mitotic activity were graded WHO grade II in accordance to our institutional practices and now per 2016 WHO criteria [41]. Therefore, all cases were graded per current WHO 2016 criteria. Tissue blocks with >90% tumor were selected for immunohistochemistry and DNA extraction.

Recurrence was defined and recurrence-free survival (RFS) was calculated as previously described [58]. The timepoint of recurrence was established by serial imaging review [pre- and post-op magnetic resonance imaging (MRI) review or computer tomography studies when MRI was contraindicated and after resolution of post-surgical changes] and documented in the medical charts by the treating physicians (neuroradiologist and neurosurgeon); recurrence was defined as either tumor recurrence following gross total surgical resection or tumor progression (further growth) following subtotal surgical resection. Simpson grade was determined as previously described based on the surgical operative report correlated with the first post-surgical imaging study. For 11 patients Simpson grade was not available or not applicable (i.e., for one intraventricular meningioma) [58].

Immunohistochemistry

Immunohistochemistry with anti-pHH3 (Ser 10) rabbit polyclonal antibody (Cell Signaling Technology, catalog#9701L, dilution 1:100) and anti-Ki-67 mouse monoclonal antibody (DAKO, clone MIB-1, dilution 1:500) was performed as previously described [58]. Mitotic index was recorded as described previously—pHH3-labeled mitoses counted per 1000 meningioma tumor cells that were further split in three categories (≤ 2 , 3–4, and ≥ 5) [58].

Methylation analysis

DNA was extracted using the MasterPure™ Complete DNA and RNA Purification Kit (Epicentre, Madison, WI, USA) per manufacturer's protocol. A total of 500 ng of DNA per sample was processed on Infinium HumanMethylation450 BeadChip methylation platform following quality control and DNA restoration using the Infinium FFPE QC and DNA Restoration Kits (Illumina Inc., San Diego, CA, USA) in the institutional core laboratory. Following methylation profiling, samples were split in 2 groups for analysis: a training dataset ($n = 89$) and a validation dataset ($n = 51$) balanced for the number of recurrences. In order to avoid any potential treatment effect bias, all treated tumor tissues were included in the validation dataset. The training dataset comprised 85 newly diagnosed, non-treated tumors and 4 non-treated recurrent tumors. The validation dataset included 35 newly diagnosed, non-treated tumors, 7 non-treated recurrent tumors, 7 recurrent treated tumors, 1 newly diagnosed, treated tumor, and 1 metastatic treated tumor.

Raw data files (*.idat) were imported, processed, and analyzed using R 3.2.2 GUI 1.66 Mavericks build (6996) (The R Foundation for Statistical Computing [http://](http://www.R-project.org)

www.R-project.org) and JMP® Genomics 7.0 software (SAS Institute Inc., Cary, NC, USA).

Development of a baseline meningioma methylation classifier (283-bMMC)

Raw data were imported using the ChAMP R package. The following probes were removed from the analysis: probes that have failed to hybridize (with a detection p value > 0.01) in one or more samples, probes with a bead count < 3 in at least 5% of samples, probes that overlapped with single nucleotide polymorphisms and probes that aligned to multiple locations as identified by Nordlund et al. [55], as well as probes localized on X and Y chromosomes [53]. In addition, for consideration of future research endeavors we chose to eliminate the probes that were no longer represented in the new Illumina assay, the Infinium MethylationEPIC BeadChip which now replaces the HumanMethylation450 platform ($n = 31,396$ probes). Batch effect was present only in the training dataset and the ComBat batch normalization function was applied [53]. The validation dataset was BMIQ normalized [69]. The top 2000 probes based on the median average deviation score from the training dataset ($n = 89$ samples) were introduced in a non-negative matrix factorization (NMF) unsupervised learning method (NMF package) [22]. The NMF algorithm 'brunet' was selected [12] and run 50 times in order to select the best factorization rank (r) or the number of groups/clusters that best fitted the data. To check for overfitting the same parameters were used on randomized data. The best factorization rank ($r = 2$) was selected based on the highest cophenetic coefficient and the smallest value at which the decrease in the residual sum of squares (RSS) was lower than the decrease of the RSS obtained from random data (Online resource 1). Then, the final NMF model was run 50 times and 2 metagene clusters were defined by 283 probes (NMF class 1–98 probes and 34 samples and NMF class 2–185 probes and 55 samples) (Online resource 1). Supervised hierarchical clustering (HC) was run on the training dataset with only these 283 probes and the probes respected the NMF classes following clustering. Because 3 samples switched class following HC they were eliminated and the final methylation model (283-bMMC) was defined by 86 samples and 283 probes. The reasons for divergent classification based on analytical methods can be multiple and range from factors pertaining to bioinformatics pipeline analyses to the possibility that these 3 cases may not have fit either group as robustly compared to the remainder of the cases. The clinical information for the 3 eliminated samples is offered in Online Resource 2.

Optimization of a meningioma methylation predictor (MMP)

In order to maximize prediction of RFS, we further optimized a meningioma methylation predictor on the training dataset. The 283 probes derived from 283-bMMC were introduced into a support vector machine (SVM) classification method with radial-basis smoothing kernel (RBM) [19, 20]. Deviance residuals were calculated and were used further as continuous predictor variables for model selection. The genetic algorithm SAS GENESSELECT was used for feature selection. The final model was selected based on the maximum Harrell C Statistic [23] and minimum Akaike and Bayesian information criteria [3] with the lowest possible root mean square error (RMSE). 50-fold cross-validation with 30% of the data holdout was run on the final selected model and the RMSE was documented. The RBM predictor probabilities generated were normalized by inverse transformation and a cutoff was calculated by partition analysis using the deviance residual as the dependent variable. The selected model was then independently applied to the validation dataset.

Copy number analysis

Copy number aberration (CNA) information was extracted from the 450k methylation data (intensity values) after a baseline correction for cancer samples using the maximum density peak estimation (MDPE) method (CopyNumber450kCancer R package) [49]. All samples were reviewed manually as well as using Integrative Genomics Viewer (IGV) v. 2.3.68 (97) (hg19) for detailed partial/segmental annotation. (For more details and few examples please see Online resource 3.)

Survival and other analyses

Summary statistics, Chi-square, Fisher's exact test, two-sample Wilcoxon test (Mann–Whitney), Cox uni- and multi-variable analyses, Log-rank and Kaplan–Meier survival graphics were generated in R 3.2.2 GUI 1.66 Mavericks build (6996) (The R Foundation for Statistical Computing <http://www.R-project.org>). Reported median survivals were calculated via Kaplan–Meier method. Probe (cg loci) annotation was retrieved from the Illumina 450k manifest file and UCSC Genome Browser using the GRCh37/hg19 assembly. Gene ontology and pathway analysis was performed using QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, CA, USA www.qiagen.com/ingenuity) (v. 27821452). All IPA *p* values were calculated using a right-tailed Fisher's exact test. For comparisons of methylation levels a Mann–Whitney test was run after Bonferroni correction for multiple sample

comparison. CpG appartenance to promoter region was determined using the Genome Browser tool of Genomatrix Software Suite (v. 3.6). Details on CNAs selection for uni- and multi-variable analyses are presented in Online resource 4. *P* values ≤ 0.05 were considered statistically significant.

Results

Most tumors (98%) were graded based on mitotic activity. No tumor was graded as atypical (WHO grade II) solely based on the presence of atypical morphological features. Overall, 12 tumors had brain invasion of which only 3 were graded as atypical based on brain invasion only. The training dataset consisted of 89 samples and included 25 patients (28%) that experienced tumor recurrence at a median of 1.57 years. Median follow-up time was 7.02 years. The validation dataset ($n = 51$ samples) included 22 patients (43%) that experienced tumor recurrence at a median of 3.6 years and had a median follow-up time of 6.27 years. Detailed clinical characteristics of the datasets are provided in Table 1. Overall, as expected, most patients were females with a F:M ratio of 2.33. A single pediatric patient was included (age <18 years). With respect to location, the non-skull base vs. skull base ratio was 1.69.

The training methylation dataset was initially analyzed to identify clinically significant methylation signatures. Using NMF unsupervised classification on top differentially methylated CpG loci, a final baseline meningioma methylation classifier (283-bMMC) was defined by 86 samples and 283 probes (Fig. 1). The 283-bMMC separated 2 meningioma methylation subgroups: a clinically favorable prognostic subgroup (MM-FAV) ($n = 31$, hypermethylated CpG loci = 98) (median RFS not reached, range 0.27–16.6 years) and a clinically unfavorable meningioma methylation subgroup (MM-UNFAV) ($n = 55$, hypermethylated CpG loci = 185) (log-rank $p = 0.0014$) (median RFS = 12.07 years, range 0.31–17.61 years) (Fig. 1). When 283-bMMC was applied to the 51-sample validation dataset it validated the subgroup signatures and the difference in RFS (log-rank $p = 0.049$) with a median RFS of 16.35 years (range 0.86–16.35) for the MM-FAV group and of 8.27 years (range 1.10–12.62) for the MM-UNFAV group (Fig. 2). Overall, most WHO grade II (~80%) and all anaplastic meningiomas classified as MM-UNFAV. This subgroup included tumors with significantly higher median Ki-67 (MIB-1) proliferation index, shorter RFS, that were diagnosed at an increased median age compared to tumors of the MM-FAV subgroup. Also most recurrences (41/46, ~89%, $p = 0.0001$, Fisher's exact test), skull-base meningiomas (~82%) and meningiomas of male patients (~81%) classified in the MM-UNFAV subgroup (Table 2).

Table 1 Clinical characteristics of the test ($n = 89$) and validation ($n = 51$) datasets ($n = 140$)

	Test	Validation	Overall
WHO grade, # (%) [recurrences]			
I	54 (60.67) [10]	36 (70.59) [10]	90 (64.29) [20]
II	34 (38.20) [14]	9 (17.65) [6]	43 (30.71) [20]
III	1 (1.12) [1]	6 (11.76) [6]	7 (5) [7]
Median F/U, (range) (years)	7.02 (0.27–17.61)	6.27 (0.10–16.35)	6.75 (0.10–17.61)
Median age, (range) (years)	57.26 (20.31–86.48)	56.62 (5.95–79.58)	57.02 (5.95–86.48)
Simpson grade, # (%)			
1	45 (50.56)	24 (47.06)	69 (49.29)
2	24 (26.97)	12 (23.53)	36 (25.71)
3	6 (6.74)	3 (5.88)	9 (6.43)
4	9 (10.11)	6 (11.76)	15 (10.71)
N/A	5 (5.62)	6 (11.76)	11 (7.86)
Mitotic index			
≤2	59 (66.29)	27 (52.94)	86 (61.43)
3–4	16 (17.98)	12 (23.53)	28 (20)
≥5	14 (15.73)	12 (23.53)	26 (18.57)
Median MIB-1 index, (range)	3.4 (0.2–36.4)	3.4 (0.3–54.1)	3.4 (0.2–54.1)
Sex			
F	65 (73.03)	33 (64.71)	98 (70)
M	24 (26.97)	18 (35.29)	42 (30)
Location			
Skull-base	29 (32.58)	23 (45.10)	52 (37.14)
Non-skull-base	60 (67.42)	28 (54.90)	88 (62.86)

F female, F/U follow-up, M male, WHO World Health Organization

Overall, 283-bMMC subgroups were not significant for predicting tumor recurrence after adjustment for WHO grade, mitotic index, Simpson grade, sex, location, and CNAs [$p = 0.0793$, HR = 2.97, 95% CI = (0.88–10.05)] (Table 3).

Tumors in the MM-UNFAV group had complex CNA pattern including enrichment of $-1p$, $+1q$, $-2p$, $-3p/+3$, -4 , $+5$, $-6q$, $+9$, -10 , $+12$, $+13q$, $-14q$, $+15q$, -16 , -18 , $+20$, $+21q$, $+22q$ compared to tumors in the MM-FAV group which consisted mainly of $+1p$ and $-22q$ (Figs. 1, 2). Overall, among recurrent CNAs in the samples overall, $-1p$, $+1q$, $-6q$, $-14q$, and $-18q$ were significantly linked to meningioma recurrence (Online resource 4).

In order to maximize prediction of aggressive meningioma and improve classification for the poor prognostic subgroup (Online resource 5), the 283 probes defining 283-bMMC were introduced in an RBM prediction algorithm. Unsupervised variable selection followed by RBM resulted in an optimized 64-CpG locus meningioma methylation predictor (64-MMP) with a negligible 50-fold cross-validation RMSE of 0.15 (Fig. 3a). Partition analysis of the inverse transformed predictor probabilities returned the cut-off of 0.3813. Predictor probabilities >0.3813 (64-MMP-UNFAV) separated all recurrences (24/24) and patients


classified in this poor prognosis group had significantly decreased median RFS (1.48 years, range 0.31–12.07) compared to those with predictor probabilities ≤ 0.3813 (64-MMP-FAV) (median RFS = not reached, range 0.27–17.61) (log-rank $p < 0.0001$) (Fig. 3a).

When applied to the validation dataset, the 64-MMP significantly improved stratification (log-rank $p = 0.0004$) with a median RFS of 3.60 years (range 0.45–10.84) for the 64-MMP-UNFAV group compared to 16.35 years (range 0.10–16.35) for the 64-MMP-FAV group (Fig. 3b).

Overall, the 64-MMP was predictive of tumor recurrence after adjustment for WHO grade, mitotic index, Simpson grade, sex, location, and CNAs [$p < 0.0001$, HR = 12.16, 95% CI = (5.16–28.67)] (Table 3).

The 283-bMMC probes were located on 157 gene regions (52 genes for the MM-FAV group and 105 for the MM-UNFAV group). The subset of 64-MMC probes was located on 44 gene regions (identified with details in Online Resource 6). An overview of the gene function associated with the 283-bMMC probes and their subcellular location is provided in Online resource 7. The signaling and metabolic canonical pathways mapped were G-protein coupled receptor signaling, axonal guidance signaling, cAMP-mediated signaling, WNT/ β -catenin signaling, and AMPK signaling. Molecules were also involved in thrombin

Fig. 1 Supervised hierarchical clustering with the 283 probes in the training dataset ($n = 86$) separates 2 differentially methylated groups of tumors. The copy number information is represented at the bottom. Each row represents a probe and each column represents a sample. Methylation values are shown after batch normalization. Kaplan–Meier survival analysis illustrates significantly decreased tumor recurrence time for patients with meningioma from the MM-UNFAV group




signaling, glucocorticoid receptor signaling, protein kinase A signaling, ERK/MAPK, PI3K/AKT and PTEN signaling, mTOR, p53, NF- κ B signaling, but also in IL-6, IL-8 and IL-12 signaling. For direct and indirect relationships among these molecules as well as relationships with other molecules that have been described to be involved in meningioma pathogenesis see Online resource 7.

In order to evaluate the biologic relevance of the genes involved in the predictors, we performed gene ontology analyses of the bMMC gene regions containing at least 3 hypermethylated CpG in the gene regulatory sites. These hypothetically involved genes (identified in yellow in

Online resource 6) were *DUSP6*, *GJB6*, *SLC38A4*, *STRA6* of the MM-FAV group and *REC8* and *IER* of the MM-UNFAV group. Molecule activity predictor analysis showed that molecules activated in the MM-UNFAV group support are usually inactivated in the MM-FAV group and vice versa (Online resource 7) and from the biological standpoint are involved in pathways that ultimately lead to cell proliferation and tumorigenesis; whereas this effect is less pronounced in the MM-FAV group. Interestingly, molecule predictor activity predicted NF2 inactivation in both groups of tumors. Comparison analysis showed a significant activation of the WNT/ β -catenin pathway in the MM-UNFAV

Fig. 2 Supervised hierarchical clustering with the 283 probes in the validation dataset ($n = 51$) separates 2 differentially methylated groups of tumors. The copy number information is represented at the bottom. Each row represents a probe and each column represents a sample. Methylation values are shown after BMIQ normalization. Kaplan–Meier survival analysis illustrates significantly decreased tumor recurrence time for patients with meningioma from the MM-UNFAV group



group compared to the MM-FAV group (Online resource 8).

Discussion

In this study, we demonstrate robust DNA methylation signatures in meningioma able to stratify patients by recurrence risk. By using a training/validation approach and unsupervised analyses we defined a robust basic methylation classifier (bMMC) able to separate 2 groups of

meningioma patients with significant differences in RFS (MM-FAV vs. MM-UNFAV) (Figs. 1, 2). In order to improve the prognostic effect and separation of the groups, we further optimized a meningioma methylation predictor (64-MMP) that resulted in a significantly improved effect on RFS that remained statistically significant in a multivariable model, after adjustment for relevant clinical, morphological, and molecular variables (Fig. 3; Table 3). These signatures provide proof-of-concept that methylation signatures could be used in addition to the current clinical (Simpson grade) and histological (WHO grade) predictors

Table 2 Comparison of clinical and histopathological characteristics between the 283-bMMC subgroups

	MM-FAV	MM-UNFAV	<i>p</i> value
WHO grade, # (%) [recurrences]			
I	35 (39.77) [4]	53 (60.23) [16]	<u>0.0189</u> *
II	9 (21.43) [1]	33 (78.57) [18]	
III	0 (0) [0]	7 (100) [7]	
Median F/U, (range) (years)	7.18 (0.27–16.60)	5.93 (0.10–17.61)	<u><0.0001</u> ***
Median age, (range) (years)	53 (24.82–82.15)	58.26 (5.95–86.48)	<u><0.0001</u> ***
Simpson grade, # (%)			
1	23 (33.82)	45 (66.18)	0.3990*
2	14 (41.18)	20 (58.82)	
3	1 (11.11)	8 (88.89)	
4	4 (26.67)	11 (73.33)	
N/A	2 (18.18)	9 (81.82)	
Mitotic index			
≤2	33 (38.82)	52 (61.18)	0.0658*
3–4	7 (26.92)	19 (73.08)	
≥5	4 (15.38)	22 (84.62)	
Median mitotic index (range)	1 (0–7)	2 (0–24)	0.1439***
Median MIB-1 index, (range)	2.3 (0.2–22.6)	5 (0.3–54.1)	<u><0.0001</u> ***
Sex			
F	36 (37.89)	59 (62.11)	<u>0.0294</u> **
M	8 (19.05)	34 (80.95)	
Location			
Skull-base	9 (17.65)	42 (82.35)	<u>0.0052</u> **
Non-skull-base	35 (40.70)	51 (59.30)	

Underlined values are statistically significant

F female, *F/U* follow-up, *M* male, *WHO* World Health Organization

* Fisher's exact test

** Chi-square test

*** Two-sample Wilcoxon test (Mann–Whitney)

[24, 41, 52, 66] to more accurately identify patients prone to tumor recurrence. With such information, recurrence risk might be more accurately predicted for individual patients to tailor decisions for follow-up with serial imaging and/or neurological status assessment versus the option of adjuvant radiation therapy.

In the past, several studies focused on investigating promoter methylation mainly using a targeted approach for a limited number of genes [4, 6–8, 11, 14, 15, 30, 34, 38, 47]. With time, molecular advances allowed interrogation at a larger number of CpG loci [35] culminating with the 27k and 450k methylation assays from Illumina interrogating approximately 27,000 and 450,000 CpG loci respectively [21, 74]. To the best of our knowledge only three studies addressed global methylation in meningiomas [21, 35, 74]. Kishida et al. in the first global methylation meningioma study [35] interrogated 30 WHO grade I and II meningiomas using methylated CpG island amplification

microarrays for 6157 genes and identified 198 significantly different genes among 3 clusters obtained by unsupervised hierarchical clustering and consensus clustering analysis. Cluster 1 or the low methylator phenotype contained less aggressive tumors and Clusters 2 and 3 were enriched with recurrent tumors. They concluded that 5 of 198 genes which were selected based on pathway analysis (*HOXA6*, *HOXA9*, *PENK*, *UPK3A* and *IGF2BP1*) could successfully identify recurrent tumors and could be used as epigenetic biomarkers to effectively predict a pattern of global DNA methylation in meningioma. They validated their findings in a new set of 32 WHO grade I and II meningioma tumors. Interestingly several of their hypermethylated genes of the more aggressive Cluster 3 (*ADARBI*, *IER3*, *REC8*) were also hypermethylated in our MM-UNFAV subgroup. Moreover, 2 loci of *REC8* and 1 locus of *IER3* were part of our 64-MMP. To note is that *IER3* and *REC8* had an increased number of hypermethylated CpG islands (at least 3) in the

Table 3 Cox univariable and multivariable analyses ($n = 137$, events = 46)

Variable	Univariable			Multivariable ^b					
				(With 283-bMMC)			(With 64-MMP)		
	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value
283-bMMC									
UNFAV vs. FAV	5.01	1.97–12.73	<u>0.0007</u>	2.97	0.88–10.05	0.0793			
64-MMP									
UNFAV vs. FAV	19.47	9.48–40	<u><0.0001</u>				12.16	5.16–28.67	<0.0001
CNAs									
1–2 vs. 0	2.91	1.39–6.11	<u>0.0048</u>	2.63	0.99–6.96	<u>0.0512</u>	2.42	0.95–6.18	0.0645
≥3 vs. 0	6.48	3.19–13.17	<0.0001	3.93	1.34–11.55	<u>0.0129</u>	3.41	1.10–10.54	<u>0.0330</u>
WHO grade									
II vs. I	2.90	1.53–5.50	<u>0.0011</u>	1.52	0.63–3.63	0.3480	0.98	0.37–2.58	0.9633
III vs. I	11.86	4.91–28.65	<u><0.0001</u>	2.86	0.61–13.31	0.1806	1.39	0.25–7.66	0.7023
Mitotic index									
3–4 vs. ≤2	3.03	1.41–6.50	<u>0.0044</u>	2.14	0.83–5.56	0.1162	1.45	0.56–3.75	0.4468
≥5 vs. ≤2	7.05	3.55–14.00	<u><0.0001</u>	5.18	1.72–15.63	<u>0.0035</u>	2.98	1.01–8.76	<u>0.0476</u>
Simpson grade ^a									
2 vs. 1	1.21	0.55–2.65	0.6291	2.53	0.98–6.49	<u>0.0542</u>	2.38	0.91–6.20	0.0757
3 vs. 1	3.52	1.29–9.60	<u>0.0138</u>	3.94	1.16–13.44	<u>0.0285</u>	4.63	1.22–17.57	<u>0.0243</u>
4 vs. 1	1.62	0.64–4.12	0.3095	2.57	0.84–7.88	0.0999	1.76	0.58–5.36	0.3172
Sex									
M vs. F	1.86	1.04–3.33	<u>0.0376</u>	0.96	0.44–2.09	0.9179	0.97	0.43–2.16	0.9367
Location									
Skull-base vs. non-skull-base	1.26	0.69–2.29	0.446	1.87	0.75–4.70	0.1815	2.15	0.90–5.15	0.0865

Underlined values are statistically significant

CNAs copy number aberrations, *F* female, *M* male, *WHO* World Health Organization

^a 126 cases (38 events) with complete data were introduced in the univariable model

^b 126 cases (38 events) with complete data across all variables were introduced in the model




Fig. 3 The 64-MMP model developed on the training dataset (a) and then applied to the validation dataset (b) significantly separates risk groups for meningioma recurrence

promoter region and were selected as candidates for gene downregulation and upstream/downstream molecule activity prediction (Online resource 7). In contradiction with

Kishida's findings we noted that some genes in our cohort were hypermethylated in the MM-FAV group (*GATA2* and *RAP1GAP*), whereas they reported these genes as

hypermethylated in the more aggressive tumors of Cluster 3. Also C13orf33 was hypermethylated in our MM-UNFAV group, whereas this gene was hypomethylated in Cluster 3 tumors. Although only 6 genes were in common between our and Kishida's study, several members of the same gene family were present in both. These included genes encoding ephrins, solute carrier proteins, ankyrin repeat domain and Rab family of proteins, zinc finger proteins, and calcium-voltage gated channel subunits. On the other hand, none of the 5 proposed epigenetic biomarkers were selected by our meningioma predictive model [35].

Gao et al. were the first group to introduce the Illumina 450k platform to meningioma profiling [21]. They profiled 19 WHO grade I, II and III meningiomas and similar with Vengoechea et al. [74], Gao's group looked for differences in methylation between benign and malignant meningioma groups. They concluded that WHO grade II and III meningiomas were globally hypomethylated compared to WHO grade I tumors, but they did not offer much details and probe identification except for 15 hypomethylated genes that were further investigated for expression analysis. They also mentioned that 26 genes were hypermethylated in malignant meningiomas of which 9 were *BARHL2*, *TLX3*, *FOXR1*, *HOXA11*, *HOXA6*, *HOXA9*, *OTX2*, *MAL2*, and *PAX3*. None of these genes were selected by our meningioma predictor model although in some instances members of the same gene family were present in our gene list (solute carrier proteins, paired box, and forkhead box transcription factors). It is interesting to notice that hypermethylation of *HOXA11*, *HOXA6*, and *HOXA9* were reported in aggressive meningiomas by several studies [15, 21, 35], but our analysis did not identify these genes as important predictors of outcome. However, on manual inspection of all unfiltered CpG loci located on *HOXA11*, *HOXA6*, and *HOXA9*, there were significant differences with increased levels of methylation in the MM-UNFAV group compared to MM-FAV group (findings limited to the validation dataset) (Online resource 9) confirming the findings in the literature.

Vengoechea et al. [74] profiled 33 WHO grade I and II meningiomas using the 27k Illumina methylation array and validated their finding on additional 7 tumor replicates and 12 additional independent WHO grade I and II meningioma samples using the 450k Illumina methylation array. They performed hierarchical unsupervised clustering analysis with the top differentially methylated probes between WHO grade I and atypical (WHO grade II) meningiomas (95 in the discovery set and 87 in the validation set) but they did not offer details on which of these probes were predominantly hypermethylated in the more aggressive (WHO grade II) meningiomas. They selected 9 probes based on differential methylation between the groups;

however, based on their presented results their association was weak [74].

A generally recognized epigenetic meningioma biomarker of interest is *TIMP3* hypermethylation, which along with *TIMP3* under-expression has been described as common in anaplastic meningiomas [7, 8]. This gene did not include predictive hypermethylated loci in our analysis, but on manual inspection *TIMP3* had significant differential methylation in 3 loci with hypermethylation in 2 loci of the MM-FAV group and one locus of the MM-UNFAV group (validation dataset only) (Online resource 9). This is likely because our model was developed mainly on WHO grade I and II tumors (there was only 1 WHO grade III tumor in the training dataset). Further global methylation studies should be designed to include more anaplastic tumors.

Meningiomas are complex from a genomic perspective, and a number of molecular alterations have been described to date. The most common cytogenetic alteration, 22q loss, is observed across WHO grades, whereas losses of chromosomes 1p, 6q, 10, 14q, 18q and gains of chromosomes 1q, 9q, 12q, 15q, 17q, 20q enrich the WHO grade II and III tumors [16, 39, 45, 60, 75, 76]. Chromosome 9p loss is frequently associated with anaplastic astrocytomas [61, 75]. These findings were generally supported by our analyses with more complex karyotypes clustering in the MM-UNFAV subgroup [17]. Interestingly, in our cohort several tumors showed gains of 22q and in support of the published literature when present, they were more likely categorized as of unfavorable clinical course (MM-UNFAV) [44, 46, 63, 75] (Figs. 1, 2). However, on survival analysis this was not statistically significant (Online resource 4). Chromosome 22q gain is an interesting phenomenon that should be further investigated.

The most commonly activated signaling and metabolic canonical pathways described in meningiomas are the RB/p53 pathway, MAPK and PI3K/AKT, PLC γ /PKC-calcium signaling pathway, the cyclooxygenase-2 signaling pathway, mTOR, WNT/ β -catenin, Notch, and Hedgehog signaling pathways [16, 32, 33, 50]. This is overall in keeping with our findings (Online resource 7), noting that comparative pathway analysis identified a stronger activation of the WNT/ β -catenin signaling pathway in the MM-UNFAV subgroup opposing the activation of retinoate biosynthesis and leukocyte extravasation signaling in the MM-FAV subgroup (Online resource 8).

There are several potential limitations of our study. First, our study is limited in that the training/discovery dataset is somewhat unbalanced for WHO grades and included only one newly diagnosed anaplastic meningioma. Although the validation dataset accurately separated all anaplastic meningiomas (all WHO grade III meningiomas in the MM-UNFAV arm) (Figs. 1, 2), this model should be interpreted with care when applied to WHO grade III meningiomas.

Second, although retrieval of copy number information from the 450k array intensity values has been validated in the literature by multiple molecular platforms and the 450k platform has been identified as having the sensitivity of SNP arrays for copy number alteration detection [18, 49, 56] the results should be interpreted with care. Third, our prediction analyses based on hypothetical down-regulation of the 6 genes presented in Online resource 7, should be interpreted with care having in mind that epigenetic regulation is more complex and involves other regulatory molecules that were not taken into consideration here, such as microRNA expression and histone/chromatin modifications.

Our study is novel in that it utilizes global methylation assays and mathematical modeling on a substantive cohort of clinically annotated, non-treated meningiomas to date ($n = 89$) to offer robust methylation meningioma signatures (283-bMMC model) that characterize clinical–biological subgroups (MM-FAV and MM-UNFAV). Importantly, a subset of these 283 markers (64-MMP) proved as stronger predictors indicating that this predictor probability could potentially be used for prognostication in the clinical setting (64-MMP). Moreover, a significant strength of our study is the correlation with clinical prognostic factors and extensive available patient follow-up time. Our findings are important because our basic methylation model and methylation predictor could potentially be applied to newly diagnosed meningioma patients in order to better predict tumor recurrence. An improved, more accurate recurrence prediction is likely to facilitate patient management decisions in the clinic. While validated in our cohort, further work is needed, and we hope this work will stimulate further investigation to evaluate methylation signatures that can inform therapeutic decisions for patients with meningioma.

With the ever-increasing expansion of genomic data, future correlational studies should integrate multi-platform analyses (i.e., methylation, copy number, mutational, expression) with clinical information in order to stratify risk and impact patient management in meningioma with the ultimate goal to foster precision therapeutic approaches and improve patient outcome.

Acknowledgements AO was supported by the National Institutes of Health/National Cancer Institute (T32CA163185). KA was supported by a grant from the Canadian Institute of Health Research and support from the Princess Margaret Cancer Foundation.

References

1. Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhir R, Santagata S (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. *Neuro-oncology* 18(5):649–655. doi:[10.1093/neuonc/nov316](https://doi.org/10.1093/neuonc/nov316)
2. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG 2nd (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. *Neurosurgery* 64(1):56–60. doi:[10.1227/01.NEU.0000330399.55586.63](https://doi.org/10.1227/01.NEU.0000330399.55586.63) (discussion 60)
3. Akaike H (1974) A new look at the statistical model identification. *IEEE Trans Autom Control* 19(6):716–723
4. Amaty VJ, Takeshima Y, Inai K (2004) Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. *Mod Pathol* 17(6):705–710. doi:[10.1038/modpathol.3800111](https://doi.org/10.1038/modpathol.3800111)
5. Ashktorab H, Rahi H, Wansley D, Varma S, Shokrani B, Lee E, Daremipouran M, Laiyemo A, Goel A, Carethers JM, Brim H (2013) Toward a comprehensive and systematic methylome signature in colorectal cancers. *Epigenetics* 8(8):807–815. doi:[10.4161/epi.25497](https://doi.org/10.4161/epi.25497)
6. Aydemir F, Yurtcu E, Balci TB, Sahin FI, Gulsen S, Altinors N (2012) Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients. *Genet Test Mol Biomark* 16(5):335–340. doi:[10.1089/gtmb.2011.0245](https://doi.org/10.1089/gtmb.2011.0245)
7. Barski D, Wolter M, Reifemberger G, Riemenschneider MJ (2010) Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. *Brain Pathol* 20(3):623–631. doi:[10.1111/j.1750-3639.2009.00340.x](https://doi.org/10.1111/j.1750-3639.2009.00340.x)
8. Bello MJ, Aminos C, Lopez-Marín I, Arjona D, Gonzalez-Gomez P, Alonso ME, Lomas J, de Campos JM, Kusak ME, Vaquero J, Isla A, Gutierrez M, Sarasa JL, Rey JA (2004) DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. *Acta Neuropathol* 108(5):413–421. doi:[10.1007/s00401-004-0911-6](https://doi.org/10.1007/s00401-004-0911-6)
9. Bi WL, Zhang M, Wu WW, Mei Y, Dunn IF (2016) Meningioma genomics: diagnostic, prognostic, and therapeutic applications. *Front Surg* 3:40. doi:[10.3389/fsurg.2016.00040](https://doi.org/10.3389/fsurg.2016.00040)
10. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconail LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhir R (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. *Nat Genet* 45(3):285–289. doi:[10.1038/ng.2526](https://doi.org/10.1038/ng.2526)
11. Brokinkel B, Fischer BR, Peetz-Dienhart S, Ebel H, Sepehrnia A, Rama B, Albert FK, Stummer W, Paulus W, Hasselblatt M (2010) MGMT promoter methylation status in anaplastic meningiomas. *J Neurooncol* 100(3):489–490. doi:[10.1007/s11060-010-0202-0](https://doi.org/10.1007/s11060-010-0202-0)
12. Brunet JP, Tamayo P, Golub TR, Mesirov JP (2004) Metagenes and molecular pattern discovery using matrix factorization. *Proc Natl Acad Sci* 101(12):4164–4169. doi:[10.1073/pnas.0308531101](https://doi.org/10.1073/pnas.0308531101)
13. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhan E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeyer JM, Vortmeyer A,

- Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science* 339(6123):1077–1080. doi:[10.1126/science.1233009](https://doi.org/10.1126/science.1233009)
14. de Robles P, McIntyre J, Kalra S, Roldan G, Cairncross G, Forsyth P, Magliocco T, Hamilton M, Easaw J (2008) Methylation status of MGMT gene promoter in meningiomas. *Cancer Genet Cytogenet* 187(1):25–27. doi:[10.1016/j.cancergencyto.2008.07.006](https://doi.org/10.1016/j.cancergencyto.2008.07.006)
 15. Di Vinci A, Brigati C, Casciano I, Banelli B, Borzi L, Forlani A, Ravetti GL, Allemanni G, Melloni I, Zona G, Spaziante R, Merlo DF, Romani M (2012) HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. *Transl Res* 160(5):355–362. doi:[10.1016/j.trsl.2012.05.007](https://doi.org/10.1016/j.trsl.2012.05.007)
 16. Domingues P, Gonzalez-Tablas M, Otero A, Pascual D, Ruiz L, Miranda D, Sousa P, Goncalves JM, Lopes MC, Orfao A, Taberner MD (2015) Genetic/molecular alterations of meningiomas and the signaling pathways targeted. *Oncotarget* 6(13):10671–10688. doi:[10.18632/oncotarget.3870](https://doi.org/10.18632/oncotarget.3870)
 17. Domingues PH, Sousa P, Otero A, Goncalves JM, Ruiz L, de Oliveira C, Lopes MC, Orfao A, Taberner MD (2014) Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. *Neuro-oncology* 16(5):735–747. doi:[10.1093/neuonc/not325](https://doi.org/10.1093/neuonc/not325)
 18. Feber A, Guilhamon P, Lechner M, Fenton T, Wilson GA, Thirlwell C, Morris TJ, Flanagan AM, Teschendorff AE, Kelly JD, Beck S (2014) Using high-density DNA methylation arrays to profile copy number alterations. *Genome Biol* 15(2):R30. doi:[10.1186/gb-2014-15-2-r30](https://doi.org/10.1186/gb-2014-15-2-r30)
 19. Fernandez-Delgado M, Cernadas E, Barro S, Amorim D (2014) Do we need hundreds of classifiers to solve real world classification problems? *JMLR* 15(1):3133–3181
 20. Florido JP, Pomares H, Rojas I, Urquiza JM, Herrera LJ, Claros MG (2010) Effect of pre-processing methods on microarray-based SVM classifiers in Affymetrix genechips. *IEEE*, pp 1–6
 21. Gao F, Shi L, Russin J, Zeng L, Chang X, He S, Chen TC, Giannotta SL, Weisenberger DJ, Zada G, Mack WJ, Wang K (2013) DNA methylation in the malignant transformation of meningiomas. *PLoS One* 8(1):e54114. doi:[10.1371/journal.pone.0054114](https://doi.org/10.1371/journal.pone.0054114)
 22. Gaujoux R, Seoighe C (2010) A flexible R package for non-negative matrix factorization. *BMC Bioinform* 11:367. doi:[10.1186/1471-2105-11-367](https://doi.org/10.1186/1471-2105-11-367)
 23. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. *JAMA* 247(18):2543–2546
 24. Heald JB, Carroll TA, Mair RJ (2014) Simpson grade: an opportunity to reassess the need for complete resection of meningiomas. *Acta Neurochir (Wien)* 156(2):383–388. doi:[10.1007/s00701-013-1923-6](https://doi.org/10.1007/s00701-013-1923-6)
 25. Heim S, Sill M, Jones DT, Vasiljevic A, Jouvett A, Fevre-Montange M, Wesseling P, Beschoner R, Mittelbronn M, Kohlhof P, Hovestadt V, Johann P, Kool M, Pajtler KW, Korshunov A, Ruland V, Sperveslage J, Thomas C, Witt H, von Deimling A, Paulus W, Pfister SM, Capper D, Hasselblatt M (2016) Papillary tumor of the pineal region: a distinct molecular entity. *Brain Pathol* 26(2):199–205. doi:[10.1111/bpa.12282](https://doi.org/10.1111/bpa.12282)
 26. Herrlinger U, Jones DT, Glas M, Hattungen E, Gramatzki D, Stuplich M, Felsberg J, Bahr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. *Acta Neuropathol* 131(2):309–319. doi:[10.1007/s00401-015-1495-z](https://doi.org/10.1007/s00401-015-1495-z)
 27. Holsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, Fahlbusch R, Metzler M, Kool M, Pfister SM, von Deimling A, Capper D, Jones DT, Buslei R (2016) Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. *Acta Neuropathol Commun* 4:20. doi:[10.1186/s40478-016-0287-6](https://doi.org/10.1186/s40478-016-0287-6)
 28. Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Ryzhova M, Warnatz HJ, Ralser M, Brun S, Bunt J, Jager N, Kleinheinz K, Erkek S, Weber UD, Bartholomae CC, von Kalle C, Lawerenz C, Eils J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor MD, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya RJ, Eils R, Yaspo ML, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P (2014) Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. *Nature* 510(7506):537–541. doi:[10.1038/nature13268](https://doi.org/10.1038/nature13268)
 29. Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R, Cavalli FM, Ramaswamy V, Zapatka M, Reifenberger G, Rutkowski S, Schick M, Bewerunge-Hudler M, Korshunov A, Lichter P, Taylor MD, Pfister SM, Jones DT (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. *Acta Neuropathol* 125(6):913–916. doi:[10.1007/s00401-013-1126-5](https://doi.org/10.1007/s00401-013-1126-5)
 30. Jabini R, Moradi A, Afsharnezhad S, Ayatollahi H, Behravan J, Raziiee HR, Mosaffa F (2014) Pathodiagnostic parameters and evaluation of O(6)-methyl guanine methyl transferase gene promoter methylation in meningiomas. *Gene* 538(2):348–353. doi:[10.1016/j.gene.2013.12.039](https://doi.org/10.1016/j.gene.2013.12.039)
 31. Johann PD, Hovestadt V, Thomas C, Jeibmann A, Hess K, Bens S, Oyen F, Hawkins C, Pierson CR, Aldape K, Kim SP, Widling E, Sumerauer D, Hauser P, van Landeghem F, Ryzhova M, Korshunov A, Capper D, Jones DT, Pfister SM, Schneppenheim R, Siebert R, Paulus W, Fruhwald MC, Kool M, Hasselblatt M (2016) Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. *Brain Pathol*. doi:[10.1111/bpa.12413](https://doi.org/10.1111/bpa.12413)
 32. Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS (2002) Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. *J Neurosurg* 97(3):668–675. doi:[10.3171/jns.2002.97.3.0668](https://doi.org/10.3171/jns.2002.97.3.0668)
 33. Johnson MD, Woodard A, Kim P, Frexes-Steed M (2001) Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. *J Neurosurg* 94(2):293–300. doi:[10.3171/jns.2001.94.2.0293](https://doi.org/10.3171/jns.2001.94.2.0293)
 34. Kandenwein JA, Park-Simon TW, Schramm J, Simon M (2011) uPA/PAI-1 expression and uPA promoter methylation in meningiomas. *J Neurooncol* 103(3):533–539. doi:[10.1007/s11060-010-0411-6](https://doi.org/10.1007/s11060-010-0411-6)
 35. Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F, Sekido Y, Wakabayashi T (2012) Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. *Carcinogenesis* 33(2):436–441. doi:[10.1093/carcin/bgr260](https://doi.org/10.1093/carcin/bgr260)
 36. Koelsche C, Hovestadt V, Jones DT, Capper D, Sturm D, Sahm F, Schrimpf D, Adeberg S, Bohmer K, Hagenlocher C, Mechttersheimer G, Kohlhof P, Muhleisen H, Beschoner R, Hartmann C, Braczynski AK, Mittelbronn M, Buslei R, Becker A, Grote A, Urbach H, Staszewski O, Prinz M, Hewer E, Pfister SM, von Deimling A, Reuss DE (2015) Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. *Brain Pathol* 25(2):202–208. doi:[10.1111/bpa.12228](https://doi.org/10.1111/bpa.12228)
 37. Korshunov A, Jakobienc FA, Eberhart CG, Hovestadt V, Capper D, Jones DT, Sturm D, Stagner AM, Edward DP, Eagle RC, Proia

- AD, Koch A, Ryzhova M, Ektova A, Schuller U, Zheludkova O, Lichter P, von Deimling A, Pfister SM, Kool M (2015) Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multi-layered rosettes confirms that they are distinct nosologic entities. *Neuropathology* 35(6):538–544. doi:[10.1111/neup.12227](https://doi.org/10.1111/neup.12227)
38. Larijani L, Madjd Z, Samadikuchaksaraei A, Younespour S, Zham H, Rakhshan A, Mohammadi F, Rahbari A, Moradi A (2014) Methylation of O6-methyl guanine methyltransferase gene promoter in meningiomas—comparison between tumor grades I, II, and III. *Asian Pac J Cancer Prev* 15(1):33–38
39. Linsler S, Kraemer D, Driess C, Oertel J, Kammers K, Rahnenfuhrer J, Ketter R, Urbach S (2014) Molecular biological determinations of meningioma progression and recurrence. *PLoS One* 9(4):e94987. doi:[10.1371/journal.pone.0094987](https://doi.org/10.1371/journal.pone.0094987)
40. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of tumours of the central nervous system, 4th edn. IARC, Lyon (France)
41. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Raifenger G, von Deimling A (2016) WHO classification of tumours of the central nervous system, 4th revised edn. IARC, Lyon
42. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jager N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis T, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, Agnihotri S, Cavalli FM, Clarke I, Nethery-Brookx K, Creasy CL, Verma SK, Koster J, Wu X, Yao Y, Milde T, Sin-Chan P, Zuccaro J, Lau L, Pereira S, Castelo-Branco P, Hirst M, Marra MA, Roberts SS, Fuels D, Massimi L, Cho YJ, Van Meter T, Grajkowska W, Lach B, Kulozik AE, von Deimling A, Witt O, Scherer SW, Fan X, Muraszko KM, Kool M, Pomeroy SL, Gupta N, Phillips J, Huang A, Tabori U, Hawkins C, Malkin D, Kongkham PN, Weiss WA, Jabado N, Rutka JT, Bouffet E, Korbel JO, Lupien M, Aldape KD, Bader GD, Eils R, Lichter P, Dirks PB, Pfister SM, Korshunov A, Taylor MD (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. *Nature* 506(7489):445–450. doi:[10.1038/nature13108](https://doi.org/10.1038/nature13108)
43. Maier H, Ofner D, Hittmair A, Kitz K, Budka H (1992) Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. *J Neurosurg* 77(4):616–623. doi:[10.3171/jns.1992.77.4.0616](https://doi.org/10.3171/jns.1992.77.4.0616)
44. Maillo A, Diaz P, Sayagues JM, Blanco A, Tabernero MD, Ciudad J, Lopez A, Goncalves JM, Orfao A (2001) Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. *Cancer* 92(2):377–385
45. Maillo A, Orfao A, Espinosa AB, Sayagues JM, Merino M, Sousa P, Lara M, Tabernero MD (2007) Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. *Neuro-oncology* 9(4):438–446. doi:[10.1215/15228517-2007-026](https://doi.org/10.1215/15228517-2007-026)
46. Maillo A, Orfao A, Sayagues JM, Diaz P, Gomez-Moreta JA, Caballero M, Santamarta D, Santos-Briz A, Morales F, Tabernero MD (2003) New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. *J Clin Oncol* 21(17):3285–3295. doi:[10.1200/JCO.2003.07.156](https://doi.org/10.1200/JCO.2003.07.156)
47. Majchrzak-Celinska A, Paluszczak J, Szalata M, Barciszewska AM, Nowak S, Baer-Dubowska W (2015) DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade. *J Cancer Res Clin Oncol* 141(9):1593–1601. doi:[10.1007/s00432-015-1930-5](https://doi.org/10.1007/s00432-015-1930-5)
48. Marzese DM, Huynh JL, Kawas NP, Hoon DS (2014) Multi-platform genome-wide analysis of melanoma progression to brain metastasis. *Genom Data* 2:150–152. doi:[10.1016/j.gdata.2014.06.007](https://doi.org/10.1016/j.gdata.2014.06.007)
49. Marzouka NA, Nordlund J, Backlin CL, Lonnerholm G, Syvanen AC, Carlsson Almlöf J (2016) CopyNumber450kCancer: baseline correction for accurate copy number calling from the 450k methylation array. *Bioinformatics* 32(7):1080–1082. doi:[10.1093/bioinformatics/btv652](https://doi.org/10.1093/bioinformatics/btv652)
50. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K (2005) Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. *Clin Cancer Res* 11(11):4074–4082. doi:[10.1158/1078-0432.CCR-04-2550](https://doi.org/10.1158/1078-0432.CCR-04-2550)
51. Merino DM, Shlien A, Villani A, Pienkowska M, Mack S, Ramaswamy V, Shih D, Tatevossian R, Novokmet A, Choufani S, Dvir R, Ben-Arush M, Harris BT, Hwang EI, Lulla R, Pfister SM, Achatz MI, Jabado N, Finlay JL, Weksberg R, Bouffet E, Hawkins C, Taylor MD, Tabori U, Ellison DW, Gilbertson RJ, Malkin D (2015) Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. *Clin Cancer Res* 21(1):184–192. doi:[10.1158/1078-0432.CCR-14-1324](https://doi.org/10.1158/1078-0432.CCR-14-1324)
52. Moon HS, Jung S, Jang WY, Jung TY, Moon KS, Kim IY (2012) Intracranial meningiomas, WHO Grade II: prognostic implications of clinicopathologic features. *J Korean Neurosurg Soc* 52(1):14–20. doi:[10.3340/jkns.2012.52.1.14](https://doi.org/10.3340/jkns.2012.52.1.14)
53. Morris TJ, Beck S (2015) Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data. *Methods* 72:3–8. doi:[10.1016/j.ymeth.2014.08.011](https://doi.org/10.1016/j.ymeth.2014.08.011)
54. NCC N (2015) Clinical practice guidelines in oncology. Central nervous system cancers. Version 1. <http://www.nccn.org>. Accessed 26 July 2015
55. Nordlund J, Backlin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, Flaegstad T, Forestier E, Frost BM, Harila-Saari A, Heyman M, Jonsson OG, Larsson R, Palle J, Ronnblom L, Schmiegelow K, Sinnett D, Soderhall S, Pastinen T, Gustafsson MG, Lonnerholm G, Syvanen AC (2013) Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. *Genome Biol* 14(9):r105. doi:[10.1186/gb-2013-14-9-r105](https://doi.org/10.1186/gb-2013-14-9-r105)
56. Nordlund J, Backlin CL, Zachariadis V, Cavellier L, Dahlberg J, Ofverholm I, Barbany G, Nordgren A, Overnas E, Abrahamsson J, Flaegstad T, Heyman MM, Jonsson OG, Kanerva J, Larsson R, Palle J, Schmiegelow K, Gustafsson MG, Lonnerholm G, Forestier E, Syvanen AC (2015) DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. *Clin Epigenet* 7:11. doi:[10.1186/s13148-014-0039-z](https://doi.org/10.1186/s13148-014-0039-z)
57. Noshmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 17(5):510–522. doi:[10.1016/j.ccr.2010.03.017](https://doi.org/10.1016/j.ccr.2010.03.017)
58. Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, DeMonte F, Fuller GN, Aldape KD (2015) Mitotic index is an independent predictor of recurrence-free survival in meningioma. *Brain Pathol* 25(3):266–275. doi:[10.1111/bpa.12174](https://doi.org/10.1111/bpa.12174)
59. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. *Neuro-oncology* 17(Suppl 4):iv1–iv62. doi:[10.1093/neuonc/nov189](https://doi.org/10.1093/neuonc/nov189)

60. Ozaki S, Nishizaki T, Ito H, Sasaki K (1999) Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. *J Neurooncol* 41(2):167–174
61. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW (2002) A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. *Brain Pathol* 12(2):183–190
62. Peyre M, Kalamirides M (2014) Molecular genetics of meningiomas: building the roadmap towards personalized therapy. *Neurochirurgie*. doi:[10.1016/j.neuchi.2014.06.007](https://doi.org/10.1016/j.neuchi.2014.06.007)
63. Prowald A, Wemmert S, Biehl C, Storck S, Martin T, Henn W, Ketter R, Meese E, Zang KD, Steudel WI, Urbschat S (2005) Interstitial loss and gain of sequences on chromosome 22 in meningiomas with normal karyotype. *Int J Oncol* 26(2):385–393
64. Rohrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DT, Bewerunge-Hudler M, Becker A, Weis J, Mawrin C, Mittelbronn M, Perry A, Mautner VF, Mechttersheimer G, Hartmann C, Okuducu AF, Arp M, Seiz-Rosenhagen M, Hanggi D, Heim S, Paulus W, Schittenhelm J, Ahmadi R, Herold-Mende C, Unterberg A, Pfister SM, von Deimling A, Reuss DE (2016) Methylation-based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathol* 131(6):877–887. doi:[10.1007/s00401-016-1540-6](https://doi.org/10.1007/s00401-016-1540-6)
65. Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, Brehmer S, Schittenhelm J, Becker A, Brokinkel B, Schmidt M, Ull T, Gousias K, Kessler AF, Lamszus K, Debus J, Mawrin C, Kim YJ, Simon M, Ketter R, Paulus W, Aldape KD, Herold-Mende C, von Deimling A (2016) TERT promoter mutations and risk of recurrence in meningioma. *J Natl Cancer Inst*. doi:[10.1093/jnci/djv377](https://doi.org/10.1093/jnci/djv377)
66. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. *J Neurol Neurosurg Psychiatry* 20(1):22–39
67. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtl KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Lastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lotsch D, Berger W, Slave I, Haberler C, Jouvett A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Fruhwald MC, Milde T, Hasselblatt M, Wesseling P, Rossler J, Schuller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M (2016) New brain tumor entities emerge from molecular classification of CNS-PNETs. *Cell* 164(5):1060–1072. doi:[10.1016/j.cell.2016.01.015](https://doi.org/10.1016/j.cell.2016.01.015)
68. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fruhwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Durken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bogner L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell* 22(4):425–437. doi:[10.1016/j.ccr.2012.08.024](https://doi.org/10.1016/j.ccr.2012.08.024)
69. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S (2013) A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450k DNA methylation data. *Bioinformatics* 29(2):189–196. doi:[10.1093/bioinformatics/bts680](https://doi.org/10.1093/bioinformatics/bts680)
70. Thomas C, Sill M, Ruland V, Witten A, Hartung S, Kordes U, Jeibmann A, Beschoner R, Keyvani K, Bergmann M, Mittelbronn M, Pietsch T, Felsberg J, Monoranu CM, Varlet P, Hauser P, Olar A, Grundy RG, Wolff JE, Korshunov A, Jones DT, Bewerunge-Hudler M, Hovestadt V, von Deimling A, Pfister SM, Paulus W, Capper D, Hasselblatt M (2016) Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. *Neuro-oncology* 18(6):790–796. doi:[10.1093/neuonc/nov322](https://doi.org/10.1093/neuonc/nov322)
71. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature* 483(7390):479–483. doi:[10.1038/nature10866](https://doi.org/10.1038/nature10866)
72. van Alkemade H, de Leau M, Dieleman EM, Kardaun JW, van Os R, Vandertop WP, van Furth WR, Stalpers LJ (2012) Impaired survival and long-term neurological problems in benign meningioma. *Neuro-oncology* 14(5):658–666. doi:[10.1093/neuonc/nos013](https://doi.org/10.1093/neuonc/nos013)
73. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ (2011) A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. *Clin Cancer Res* 17(22):7148–7155. doi:[10.1158/1078-0432.CCR-11-1274](https://doi.org/10.1158/1078-0432.CCR-11-1274)
74. Vengoechea J, Sloan AE, Chen Y, Guan X, Ostrom QT, Kerstetter A, Capella D, Cohen ML, Wolinsky Y, Devine K, Selman W, Barnett GH, Warnick RE, McPherson C, Chiocca EA, Elder JB, Barnholtz-Sloan JS (2013) Methylation markers of malignant potential in meningiomas. *J Neurosurg* 119(4):899–906. doi:[10.3171/2013.7.JNS13311](https://doi.org/10.3171/2013.7.JNS13311)
75. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P (1997) Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. *Proc Natl Acad Sci* 94(26):14719–14724
76. Zang KD (2001) Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. *Cytogenet Cell Genet* 93(3–4):207–220